Literature DB >> 24760422

No causal association identified for human papillomavirus infections in lung cancer.

Devasena Anantharaman1, Tarik Gheit2, Tim Waterboer3, Gordana Halec3, Christine Carreira4, Behnoush Abedi-Ardekani5, Sandrine McKay-Chopin2, David Zaridze6, Anush Mukeria6, Neonila Szeszenia-Dabrowska7, Jolanta Lissowska8, Dana Mates9, Vladimir Janout10, Lenka Foretova11, Vladimir Bencko12, Peter Rudnai13, Eleonora Fabianova14, Anne Tjønneland15, Ruth C Travis16, Heiner Boeing17, J Ramón Quirós18, Mikael Johansson19, Vittorio Krogh20, H Bas Bueno-de-Mesquita21, Anastasia Kotanidou22, Françoise Clavel-Chapelon23, Elisabete Weiderpass24, Mattias Johansson1, Michael Pawlita3, Ghislaine Scelo1, Massimo Tommasino2, Paul Brennan25.   

Abstract

Human papillomavirus (HPV) infections have been implicated in lung carcinogenesis, but causal associations remain uncertain. We evaluated a potential causal role for HPV infections in lung cancer through an analysis involving serology, tumor DNA, RNA, and p16 protein expression. Association between type-specific HPV antibodies and risk of lung cancer was examined among 3,083 cases and 4,328 controls in two case-control studies (retrospective) and one nested case-control study (prospective design). Three hundred and thirty-four available tumors were subjected to pathologic evaluation and subsequent HPV genotyping following stringent conditions to detect all high-risk and two low-risk HPV types. All HPV DNA-positive tumors were further tested for the expression of p16 protein and type-specific HPV mRNA. On the basis of the consistency of the results, although HPV11 and HPV31 E6 antibodies were associated with lung cancer risk in the retrospective study, no association was observed in the prospective design. Presence of type-specific antibodies correlated poorly with the presence of the corresponding HPV DNA in the tumor. Although nearly 10% of the lung tumors were positive for any HPV DNA (7% for HPV16 DNA), none expressed the viral oncogenes. No association was observed between HPV antibodies or DNA and lung cancer survival. In conclusion, we found no supportive evidence for the hypothesized causal association between HPV infections and lung cancer. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24760422     DOI: 10.1158/0008-5472.CAN-13-3548

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Association between human papillomavirus and EGFR mutations in advanced lung adenocarcinoma.

Authors:  Ming Li; Fang Deng; Li-Ting Qian; Shui-Ping Meng; Yang Zhang; Wu-Lin Shan; Xiao-Lei Zhang; Bao-Long Wang
Journal:  Oncol Lett       Date:  2016-07-12       Impact factor: 2.967

Review 2.  Microbiota dysbiosis in select human cancers: Evidence of association and causality.

Authors:  Jie Chen; Jada C Domingue; Cynthia L Sears
Journal:  Semin Immunol       Date:  2017-08-16       Impact factor: 11.130

3.  Antibodies as biomarkers for cancer risk: a systematic review.

Authors:  Maria J Monroy-Iglesias; Silvia Crescioli; Kerri Beckmann; Nga Le; Sophia N Karagiannis; Mieke Van Hemelrijck; Aida Santaolalla
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

4.  Prior human polyomavirus and papillomavirus infection and incident lung cancer: a nested case-control study.

Authors:  Danny V Colombara; Lisa E Manhart; Joseph J Carter; Stephen E Hawes; Noel S Weiss; James P Hughes; Matt J Barnett; Gary E Goodman; Jennifer S Smith; You-Lin Qiao; Denise A Galloway
Journal:  Cancer Causes Control       Date:  2015-09-28       Impact factor: 2.506

5.  Mucosal alpha-papillomaviruses are not associated with esophageal squamous cell carcinomas: Lack of mechanistic evidence from South Africa, China and Iran and from a world-wide meta-analysis.

Authors:  Gordana Halec; Markus Schmitt; Sam Egger; Christian C Abnet; Chantal Babb; Sanford M Dawsey; Christa Flechtenmacher; Tarik Gheit; Martin Hale; Dana Holzinger; Reza Malekzadeh; Philip R Taylor; Massimo Tommasino; Margaret I Urban; Tim Waterboer; Michael Pawlita; Freddy Sitas
Journal:  Int J Cancer       Date:  2016-01-21       Impact factor: 7.396

6.  Association between clinical characteristics and the diagnostic accuracy of circulating single-molecule amplification and resequencing technology on detection epidermal growth factor receptor mutation status in plasma of lung adenocarcinoma.

Authors:  Chao Shi; Yan Zheng; Yin Li; Haibo Sun; Shilei Liu
Journal:  J Clin Lab Anal       Date:  2017-07-03       Impact factor: 2.352

7.  Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer.

Authors:  Devasena Anantharaman; Behnoush Abedi-Ardekani; Daniel C Beachler; Tarik Gheit; Andrew F Olshan; Kathy Wisniewski; Victor Wunsch-Filho; Tatiana N Toporcov; Eloiza H Tajara; José Eduardo Levi; Raquel A Moyses; Stefania Boccia; Gabriella Cadoni; Guido Rindi; Wolfgang Ahrens; Franco Merletti; David I Conway; Sylvia Wright; Christine Carreira; Helene Renard; Priscilia Chopard; Sandrine McKay-Chopin; Ghislaine Scelo; Massimo Tommasino; Paul Brennan; Gypsyamber D'Souza
Journal:  Int J Cancer       Date:  2017-02-14       Impact factor: 7.396

8.  Up-regulation of FOXM1 by E6 oncoprotein through the MZF1/NKX2-1 axis is required for human papillomavirus-associated tumorigenesis.

Authors:  Po-Ming Chen; Ya-Wen Cheng; Yao-Chen Wang; Tzu-Chin Wu; Chih-Yi Chen; Huei Lee
Journal:  Neoplasia       Date:  2014-11-20       Impact factor: 5.715

9.  Tobacco smoke activates human papillomavirus 16 p97 promoter and cooperates with high-risk E6/E7 for oxidative DNA damage in lung cells.

Authors:  Nelson Peña; Diego Carrillo; Juan P Muñoz; Jonás Chnaiderman; Ulises Urzúa; Oscar León; Maria L Tornesello; Alejandro H Corvalán; Ricardo Soto-Rifo; Francisco Aguayo
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

10.  Associations between human papillomavirus and history of cancer among U.S. adults in the National Health and Nutrition Examination Survey (2003-2010).

Authors:  B Liu; E Taioli
Journal:  Br J Cancer       Date:  2014-07-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.